NCT02739009View on ClinicalTrials.gov

First in Human of Single and Multiple Doses of MOR106

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

August 1, 2017

Study Completion Date

August 1, 2017

Conditions
HealthyDermatitis, Atopic
Interventions
DRUG

MOR106 single ascending doses, intravenous

DRUG

Placebo single ascending doses, intravenous

DRUG

MOR106 multiple ascending doses, intravenous

DRUG

Placebo multiple intravenous administrations

Trial Locations (4)

Unknown

SGS LSS Clinical Pharmacology Unit, Antwerp

St Johns Hospital, Budapest

• Arensia Phase I unit, Chisinau

Arensia Phase I unit, Bucharest

Sponsors

Lead Sponsor

Galapagos NV

Collaborators (1)

MorphoSys AG
All Listed Sponsors
collaborator

MorphoSys AG

INDUSTRY

lead

Galapagos NV

INDUSTRY

NCT02739009 - First in Human of Single and Multiple Doses of MOR106 | Biotech Hunter | Biotech Hunter